News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
140,230 Results
Type
Article (5516)
Company Profile (7)
Press Release (134707)
Multimedia
Podcasts (13)
Webinars (4)
Section
Business (53173)
Career Advice (143)
Deals (14334)
Drug Delivery (22)
Drug Development (12014)
Employer Resources (21)
FDA (1470)
Job Trends (2749)
News (78114)
Policy (3690)
Tag
2024 BioCapital Digital (1)
2024 Biotech Bay Standard (3)
2024 Genetown Standard (1)
2024 Lone Star Bio Digital (1)
2026 BioCapital Standard (1)
Academia (216)
Accelerated approval (1)
Allergies (13)
Alliances (7233)
ALS (13)
Alzheimer's disease (178)
Antibody-drug conjugate (ADC) (30)
Approvals (1468)
Artificial intelligence (61)
Autoimmune disease (8)
Automation (1)
Bankruptcy (134)
Best Places to Work (2050)
BIOSECURE Act (3)
Biosimilars (13)
Biotechnology (12)
Bladder cancer (11)
Brain cancer (8)
Breast cancer (33)
Cancer (438)
Cardiovascular disease (41)
Career advice (126)
Career pathing (3)
CAR-T (36)
Cell therapy (110)
Cervical cancer (5)
Clinical research (10134)
Collaboration (135)
Compensation (42)
Complete response letters (2)
COVID-19 (252)
CRISPR (7)
C-suite (86)
Cystic fibrosis (17)
Data (493)
Denatured (9)
Depression (9)
Diabetes (63)
Diagnostics (1329)
Digital health (5)
Diversity (1)
Diversity, equity & inclusion (7)
Drug discovery (24)
Drug pricing (23)
Drug shortages (7)
Duchenne muscular dystrophy (23)
Earnings (30305)
Editorial (18)
Employer branding (5)
Employer resources (19)
Events (15996)
Executive appointments (277)
FDA (1694)
Featured Employer (5)
Frontotemporal dementia (2)
Funding (477)
Gene editing (28)
Generative AI (6)
Gene therapy (93)
GLP-1 (168)
Government (298)
Guidances (26)
Healthcare (3684)
Huntington's disease (5)
IgA nephropathy (7)
Immunology and inflammation (39)
Indications (2)
Infectious disease (281)
Inflammatory bowel disease (22)
Inflation Reduction Act (5)
Influenza (9)
Intellectual property (33)
Interviews (16)
IPO (8633)
IRA (12)
Job creations (741)
Job search strategy (117)
Kidney cancer (3)
Labor market (6)
Layoffs (95)
Leadership (2)
Legal (726)
Liver cancer (15)
Lung cancer (62)
Lymphoma (29)
Machine learning (1)
Management (5)
Manufacturing (95)
MASH (32)
Medical device (3383)
Medtech (3383)
Mergers & acquisitions (6070)
Metabolic disorders (204)
Multiple sclerosis (9)
NASH (7)
Neurodegenerative disease (19)
Neuropsychiatric disorders (8)
Neuroscience (272)
NextGen: Class of 2025 (1460)
Non-profit (329)
Northern California (693)
Now hiring (1)
Obesity (111)
Opinion (55)
Ovarian cancer (10)
Pain (19)
Pancreatic cancer (24)
Parkinson's disease (18)
Partnered (4)
Patents (58)
Patient recruitment (31)
Peanut (8)
People (13460)
Pharmaceutical (5)
Pharmacy benefit managers (2)
Phase I (3249)
Phase II (4857)
Phase III (3067)
Pipeline (678)
Policy (37)
Postmarket research (159)
Preclinical (1352)
Press Release (8)
Prostate cancer (24)
Psychedelics (5)
Radiopharmaceuticals (84)
Rare diseases (79)
Real estate (1000)
Recruiting (8)
Regulatory (2956)
Reports (5)
Research institute (221)
Resumes & cover letters (22)
RNA editing (1)
RSV (5)
Schizophrenia (22)
Series A (100)
Series B (66)
Service/supplier (1)
Sickle cell disease (13)
Southern California (755)
Special edition (3)
Spinal muscular atrophy (2)
Sponsored (4)
Startups (2081)
State (1)
Stomach cancer (1)
Supply chain (15)
Tariffs (13)
The Weekly (4)
United States (6492)
Vaccines (75)
Venture capitalists (39)
Weight loss (79)
Women's health (9)
Worklife (1)
Date
Today (58)
Last 7 days (205)
Last 30 days (709)
Last 365 days (9815)
2025 (3008)
2024 (10371)
2023 (11444)
2022 (12183)
2021 (13577)
2020 (12366)
2019 (9240)
2018 (6763)
2017 (7254)
2016 (5592)
2015 (7544)
2014 (5462)
2013 (3791)
2012 (4079)
2011 (4503)
2010 (4150)
Location
Africa (113)
Alabama (10)
Alaska (2)
Arizona (39)
Arkansas (2)
Asia (8527)
Australia (1406)
California (1760)
Canada (772)
China (85)
Colorado (92)
Connecticut (116)
Delaware (22)
Europe (17177)
Florida (282)
Georgia (55)
Idaho (10)
Illinois (91)
India (7)
Indiana (71)
Iowa (2)
Japan (22)
Kansas (25)
Kentucky (1)
Louisiana (6)
Maine (19)
Maryland (166)
Massachusetts (1149)
Michigan (118)
Minnesota (111)
Mississippi (1)
Missouri (16)
Montana (4)
Nebraska (3)
Nevada (28)
New Hampshire (19)
New Jersey (473)
New Mexico (5)
New York (583)
North Carolina (278)
North Dakota (1)
Northern California (693)
Ohio (36)
Oklahoma (4)
Oregon (4)
Pennsylvania (451)
Puerto Rico (2)
Rhode Island (8)
South America (205)
South Carolina (3)
Southern California (755)
Tennessee (14)
Texas (324)
Utah (43)
Virginia (67)
Washington D.C. (9)
Washington State (178)
West Virginia (2)
Wisconsin (6)
140,230 Results for "mpm capital".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Er-Kim Announces Exclusive Distribution Agreement with Polaris Pharmaceuticals to Commercialize Pegargiminase (ADZODI) for Malignant Pleural Mesothelioma (MPM) in Multiple EMEA Markets
April 16, 2025
·
3 min read
Press Releases
Health Canada Approves KEYTRUDA® Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
April 23, 2025
·
8 min read
Press Releases
Meiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy
January 10, 2025
·
1 min read
Press Releases
MPM BioImpact Appoints Brian Shuster, Experienced in Healthcare Corporate Development, as Entrepreneur Partner
January 8, 2025
·
2 min read
Deals
What VCs really think of the market right now with MPM Capital, Endeavor and Two Bear Capital
What needs to happen for funding in biopharma to bounce back? BioSpace’s Lori Ellis discusses the macroeconomic environment and biopharma funding outlook with venture capital guests Ansbert Gadicke, Martin Gershon and Mike Goguen.
December 14, 2023
·
1 min read
·
BioSpace Insights
What VCs look for when investing with MPM Capital, Endeavor Venture Fund and Two Bear Capital
How can startup leaders support long-term sustainable growth and investment? BioSpace’s Lori Ellis speaks with venture capital guests Ansbert Gadicke, Martin Gershon and Mike Goguen for their advice and recommendations on how biopharma startups should approach funding.
December 19, 2023
·
1 min read
·
BioSpace Insights
Mergers & acquisitions
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy
The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an attempt to disrupt a merger with Alumis.
March 13, 2025
·
1 min read
·
Dan Samorodnitsky
BioCapital
Deka Biosciences Closes USD $20 Million Series B2 Financing Led by MPM BioImpact
Maryland-based biotech company Deka Biosciences announced that it has successfully closed a USD $20 Million Series B2 financing with a syndicate of life science investors led by MPM BioImpact, and joined by additional investors including Leaps by Bayer, O-Bio, Viva BioInnovator, Alexandria Venture Investments, Amana Investments, Plains Ventures, ATEM Capital and CEO John Mumm.
September 28, 2023
·
3 min read
Press Releases
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)
November 15, 2024
·
19 min read
Press Releases
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
September 18, 2024
·
19 min read
1 of 14,023
Next
